Silence Therapeutics plc
Silence Therapeutics plc (SLN.L) Stock Overview
Explore Silence Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
0
P/E Ratio
-13.44
EPS (TTM)
$-48.60
ROE
-2.17%
SLN.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Silence Therapeutics plc (SLN.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -13.44 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.